Aleigha Lawless

Aleigha Lawless

Auto-generated profile, based on publicly available information

Aleigha Lawless

Massachusetts General Hospital, Cancer Center

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
YSYi Sun
Yi Sun
LMLuke Maggs
Luke Maggs
APApekshya Panda
Apekshya Panda
SWSamuel J. Wright
Samuel J. Wright
ACAngelina M. Cicerchia
Angelina M. Cicerchia
RJRussell W. Jenkins
Russell W. Jenkins
Novel therapeutic strategies are needed to improve the efficacy of chimeric antigen receptor (CAR) T cells as a treatment of solid tumors. Multiple tumor microenvironmental factors are thought to contribute to resistance to CAR T-cell therapy in solid tumors, and appropriate model systems to identify and examine these factors using clinically relevant biospecimens are limited. In this study, we examined the activity of B7-H3–directed CAR T cells (B7-H3.CAR-T) using 3D microfluidic cultures of patient-derived organotypic tumor spheroids (PDOTS) and then confirmed the activity of B7-H3.CAR T cells in PDOTS. Although B7-H3 expression in PDOTS was associated with B7-H3.CAR-T sensitivity, mechanistic studies revealed dynamic upregulation of co-inhibitory receptors on CAR T-cells following target cell encounter that led to CAR T-cell dysfunction and limited efficacy against B7-H3–expressing tumors. PD-1 blockade restored CAR T-cell activity in monotypic and organotypic tumor spheroids with improved tumor control and upregulation of effector cytokines. Given the emerging role of TANK-binding kinase 1 (TBK1) as an immune evasion gene, we examined the effect of TBK1 inhibition on CAR T-cell efficacy. Similar to PD-1 blockade, TBK1 inhibition restored CAR T-cell activity in monotypic and organotypic tumor spheroids, prevented CAR T-cell dysfunction, and enhanced CAR T-cell proliferation. Inhibition or deletion of TBK1 also enhanced the sensitivity of cancer cells to immune-mediated killing. Taken together, our results demonstrate the feasibility and utility of ex vivo profiling of CAR T cells using PDOTS and suggest that targeting TBK1 could be used to enhance CAR T-cell efficacy by overcoming tumor-intrinsic and -extrinsic resistance mechanisms.

26 September 2025 in Science Immunology
Verified
Journal Article
Closed access
JCJung-Ho Chun
Jung-Ho Chun
BLBirkley S. Lim
Birkley S. Lim
Suyasha RoySuyasha Roy
Suyasha Roy
MWMichael J. Walsh
Michael J. Walsh
GAGita C. Abhiraman
Gita C. Abhiraman
DBDavid Baker
David Baker
Long-standing goals of cancer immunotherapy are to activate cytotoxic antitumor T cells across a range of affinities for tumor antigens while suppressing regulatory T cells. Computational protein design has enabled the precise tailoring of proteins to meet specific needs. Here, we report a de novo designed IL-21 mimic, 21h10, with high stability and signaling potency in humans and mice. In murine and ex vivo human organotypic tumor models, 21h10 showed robust antitumor activity, with more prolonged signaling and stronger antitumor activity than native IL-21. 21h10 induced pancreatitis that could be mitigated by TNF blockade without compromising antitumor efficacy. Although antidrug antibodies to 21h10 formed, they were not neutralizing. 21h10 induced highly cytotoxic T cells with a range of affinities, robustly expanding intratumoral low-affinity cytotoxic T cells and driving high expression of IFN-γ and granzyme B compared with native IL-21, while increasing the frequency of IFN-γ + T helper 1 cells and reducing regulatory T cells. The full human-mouse cross-reactivity, high stability and potency, and low-affinity antitumor responses support the translational potential of 21h10.

12 December 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
EREgle Ramelyte
Egle Ramelyte
JKJulian Kött
Julian Kött
ALAleigha R. Lawless
Aleigha R. Lawless
ACAmélie Ciernik
Amélie Ciernik
IHIsabel Heidrich
Isabel Heidrich
Christoffer GebhardtChristoffer Gebhardt
Christoffer Gebhardt
Purpose: Circulating tumor DNA (ctDNA) refers to small DNA fragments, shed from tumor cells into the bloodstream. Measuring ctDNA provides a noninvasive tool for real-time disease monitoring. Although ctDNA predicted overall survival (OS) in metastatic uveal melanoma (mUM) treated with tebentafusp, its broader prognostic value across treatment modalities remains unclear. In this study, we assess the prognostic relevance of longitudinal ctDNA detection and mutant allele fraction (MAF) in patients with mUM treated with different modalities. Experimental Design: To assess ctDNA monitoring as a tool in evaluating therapy response and clinical outcomes in patients with mUM, using an IVDR-certified digital PCR assay targeting GNAQQ209 and GNA11Q209 mutations. Results: We analyzed 655 samples from 75 patients with mUM. Absence of detectable ctDNA in baseline samples prior to first-line therapy was associated with improved OS (HR = 0.13; P = 0.02) and progression-free survival (PFS; HR = 0.31; P = 0.008). Similar associations were observed in patients treated with any line of therapy (OS: HR = 0.19, P = 0.002; PFS: HR = 0.27, P = 0.02). Detection of ctDNA within 3 months of therapy initiation was associated with worse outcomes, independent of baseline detection. Furthermore, patients with MAF > 5% any time point had a significantly poorer prognosis compared with patients with MAF < 5% (median OS 4 months vs. 21 months, P < 0.001; median PFS 2.5 months vs. 3.6 months, P = 0.004), emphasizing the added value of quantitative assessment. Conclusions: Both the presence and level of ctDNA at baseline, along with persistence of ctDNA within 3 months of starting of treatment, are strong negative prognostic markers in mUM. These findings support the clinical utility of ctDNA as a noninvasive tool for disease monitoring.

4 December 2025 in Cancer Medicine
Verified
Journal Article
Open access
DEDerek Effiom
Derek Effiom
TATyler Aprati
Tyler Aprati
AKAnastasios Karneris
Anastasios Karneris
ALAleigha Lawless
Aleigha Lawless
TSTatyana Sharova
Tatyana Sharova
SCSonia Cohen
Sonia Cohen
Purpose: A significant proportion of patients with locoregional (stage III) cutaneous melanoma recur despite adjuvant systemic therapy. Staging criteria and surgical nodal management have changed since the trials were completed. Data assessing the effect of systemic therapy compared to surveillance are limited, and factors associated with recurrence are unclear. We assessed the efficacy of adjuvant systemic therapy in real‐world patients and assessed whether baseline genomic characteristics could prognosticate or predict benefit from therapy. Methods: We collected demographic, histopathologic, clinical, and genomic data for patients diagnosed with stage III cutaneous melanoma. Outcomes of interest were recurrence‐free survival (RFS) and distant‐metastasis‐free survival (DMFS). Survival analysis was performed using the Kaplan–Meier method with log‐rank analysis. Univariate and multivariate analyses were performed using a Cox regression analysis. Results: Two hundred and fifteen patients were included, of which 65 and 76 were treated with BRAF/MEK inhibitors (BRAFi/MEKi) and anti‐PD1 adjuvant systemic therapy respectively. Seventy four underwent active surveillance. Both adjuvant therapies reduced the hazard of recurrence when compared to patients undergoing active surveillance: anti‐PD1 HR: 0.32 ( p < 0.01) and BRAFi/MEKi HR: 0.39 ( p = 0.03). Anti‐PD1‐treated patients with a BRAF V600 mutation had a shorter RFS than patients with BRAF WT melanoma ( p < 0.01); this was validated in external data where the presence of a BRAF V600 mutation was associated with an increased hazard recurrence (HR: 2.1, p = 0.025). Conclusion: Adjuvant systemic therapy improved RFS in our cohort. We found that BRAF V600 mutation was associated with a worse RFS for adjuvant anti‐PD1 monotherapy. The effect of BRAF mutation on the response to anti‐PD1 therefore may be considered when choosing between adjuvant anti‐PD1 and BRAFi/MEKi for patients with BRAF V600 mutant melanoma.

6 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
YSYingxiao Shi
Yingxiao Shi
PSPriyanka Sharma
Priyanka Sharma
JLJia-Ren Lin
Jia-Ren Lin
ADAikaterini Dedeilia
Aikaterini Dedeilia
TVTuulia Vallius
Tuulia Vallius
GBGenevieve Boland
Genevieve Boland
Mucosal melanoma is a rare, lethal melanoma subtype with distinct genetics and limited benefit from immunotherapy. To define features associated with mucosal melanoma clinical outcomes, we assembled a large, multimodally profiled cohort spanning primary and metastatic disease. Compared with cutaneous melanoma, primary mucosal melanoma showed greater genomic heterogeneity, ploidy and aneuploidy, and a more dedifferentiated, proliferative transcriptional state. Analysis of genomic sequencing of 339 patients with mucosal melanoma identified four mutually exclusive genomic subtypes: CDK4/MDM2/CCND1, SF3B1-mutated, TP53/ATRX, and mucosal melanoma Triple WT, associated with distinct anatomic sites but similar outcomes. In the tumor microenvironment, we observed reduced T cell infiltration and increased CD163 + tumor-associated macrophages in mucosal melanoma relative to cutaneous melanoma. In matched longitudinal samples, CD163 + tumor-associated macrophages increased with disease progression and immunotherapy resistance. CD163 + tumor-associated macrophages engaged non-regulatory T cells through GAL9–TIM-3 interactions, nominating TIM-3 blockade as a therapeutic strategy for mucosal melanoma. These findings define the distinct aggressive biology of mucosal melanoma and highlight potential therapeutic targets and mechanisms of immune resistance.

17 June 2026
Verified
Other
Open access
YSYi Sun
Yi Sun
LMLuke Maggs
Luke Maggs
APApekshya Panda
Apekshya Panda
SWSamuel J. Wright
Samuel J. Wright
ACAngelina M. Cicerchia
Angelina M. Cicerchia
RJRussell W. Jenkins
Russell W. Jenkins
Supplemental Figure S4 | Supporting data for ex vivo profiling of PD-1 blockade and TBK1 inhibition in combination with B7-H3.CAR-T cells using PDOTS.